Literature DB >> 7400962

Relationship of guanabenz concentrations in brain and plasma to antihypertensive effect in the spontaneously hypertensive rat.

R H Meacham, H W Ruelius, C J Kick, J R Peters, S M Kocmund, S F Sisenwine, R L Wendt.   

Abstract

The antihypertensive agent guanabenz (E-2,6-dichlorobenzylidene aminoguanidine acetate. Wy-8678) was administered i.v. in single doses of 10, 32 and 100 microgram/kg to groups of spontaneously hypertensive rats. Mean arterial blood pressure and heart rate were monitored continuously. Animals were decapitated at predetermined time intervals and concentrations of the drug in whole brain and plasma were measured by a specific gas chromatographic method. After an initial transient increase in blood pressure, significant dose-dependent maximal decreases in pressure of 15 +/- 8, 46 +/- 20 and 59 +/- 15 mm Hg (mean +/- S.D.) were observed 15 to 30 min after injection of the above respective doses. At the line of the maximal decreases in pressure (T delta max), concentrations of guanabenz in brain were 10 +/- 2, 29 +/- 8 and 89 +/- 21 ng/g and correlated significantly with dose and the magnitude of blood pressure change. The correlation between concentration in brain and change in blood pressure was also significant at subsequent sacrifice times. Concentrations of guanabenz in plasma were below the limit of detection after the 10 microgram/kg dose. At the two higher doses, concentrations in plasma were dose related but did not correlate with decreases in blood pressure. The correlation between concentration in brain and change in blood pressure is in agreement with the predominantly central mechanism of action of guanabenz.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400962

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.

Authors:  Rodney A Velliquette; Rachel Kossover; Stephen F Previs; Paul Ernsberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-01-17       Impact factor: 3.000

2.  Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.

Authors:  Xiaotian Sun; Pascaline Aimé; David Dai; Nagendran Ramalingam; John F Crary; Robert E Burke; Lloyd A Greene; Oren A Levy
Journal:  Exp Neurol       Date:  2018-02-09       Impact factor: 5.330

3.  Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis.

Authors:  Lijun Wang; Brian Popko; Emily Tixier; Raymond P Roos
Journal:  Neurobiol Dis       Date:  2014-08-15       Impact factor: 5.996

4.  Cardiovascular effects of alpha-adrenergic drugs: differences between clonidine and guanabenz.

Authors:  J S Gutkind; M Kazanietz; M A Enero
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

5.  Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis.

Authors:  Imaan Benmerzouga; Lisa A Checkley; Michael T Ferdig; Gustavo Arrizabalaga; Ronald C Wek; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

Review 6.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

7.  Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit.

Authors:  Indrajit Das; Agnieszka Krzyzosiak; Kim Schneider; Lawrence Wrabetz; Maurizio D'Antonio; Nicholas Barry; Anna Sigurdardottir; Anne Bertolotti
Journal:  Science       Date:  2015-04-10       Impact factor: 47.728

8.  Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic.

Authors:  Sharon W Way; Joseph R Podojil; Benjamin L Clayton; Anita Zaremba; Tassie L Collins; Rejani B Kunjamma; Andrew P Robinson; Pedro Brugarolas; Robert H Miller; Stephen D Miller; Brian Popko
Journal:  Nat Commun       Date:  2015-03-13       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.